Clinical trials
Malignancy clinical trials
Below are recruiting malignancy clinical trials, each written for real people, not researchers. We’re tracking 1,585 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03819296RecruitingPhase 1
Fecal transplant to treat cancer immunotherapy bowel side effects
This early-phase study tests whether changing your gut bacteria with a fecal transplant can improve diarrhea or colitis caused by cancer immunotherapy. It may help people whose symptoms have not fully settled with standard treatments like steroids and other immune-blocking medicines.
Houston, TexasAges 18 years+ - NCT03838926RecruitingPhase 1
Testing how safe and tolerable a new drug is for blood cancers
This Phase 1 study tests how safe and tolerable trichostatin A is in adults whose blood cancers have come back or did not respond to standard treatments. It may help researchers find an effective dose while monitoring side effects closely.
Washington D.C., District of ColumbiaAges 18 years+ - NCT03842085RecruitingPhase 1
MBS301 drug study for HER2-positive advanced cancers
This Phase 1 study tests MBS301, a new treatment, for people with HER2-positive advanced solid tumors. It mainly looks at safety and how the drug works, especially for cancers that have returned or spread.
ZhengzhouAges 18 years+ - NCT04068597RecruitingPhase 1/Phase 2
Testing inobrodib for blood cancers that came back
This is an early-stage study of inobrodib (CCS1477) for blood cancers like lymphoma, multiple myeloma, or acute myeloid leukemia that have returned or did not respond to standard treatment. It aims to see whether the drug is safe and can help control the cancer.
Atlanta, GeorgiaAges 18 years+ - NCT04099966RecruitingPhase 2
Stem cell transplant to treat high-risk blood cancers
This trial tests a specialized donor stem cell transplant to treat high-risk problems in the blood and bone marrow, including some cancers and non-cancers. It may help by using donor immune cells designed to better control the disease after transplant.
Valhalla, New YorkAges 1 day–30 years - NCT04114136RecruitingPhase 2
Study tests pembrolizumab or nivolumab plus a diabetes-like drug
This Phase 2 study tests whether adding a metabolic (diabetes-related) medicine to an immune therapy (pembrolizumab or nivolumab) can better control certain solid tumors. It may help people whose standard treatment would usually be pembrolizumab or nivolumab alone.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04145622RecruitingPhase 1/Phase 2
Ifinatamab deruxtecan for advanced hard-to-treat solid cancers
This early-stage trial tests an investigational antibody-drug medicine (ifinatamab deruxtecan) in people with advanced solid tumors. It aims to see whether it can shrink tumors or help control cancer, and to learn about side effects and the best way to use it.
Los Angeles, CaliforniaAges 18 years+ - NCT04151342Recruiting
Study of Canadian adults with cancer rare DNA changes
This real-world study follows adults in Canada who have cancer that was tested and found to have rare molecular (DNA/protein) changes. It helps researchers understand how these rare findings show up and how care happens in everyday practice.
Calgary, AlbertaAges 18 years+ - NCT04265430RecruitingPhase 4
MRI scans to predict normal-tissue side effects after treatment
This trial uses repeated MRI scans to better predict which patients may develop painful jaw and mouth tissue problems after radiation and/or certain bone or blood-vessel medicines. It may help clinicians spot problems earlier and tailor follow-up care.
Houston, TexasAges 18 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT04329728RecruitingPhase 1/Phase 2
Study drug for relapsed or refractory lymphoid cancers
This Phase 1/2 study tests AVM0703 in people ages 12+ with certain lymphoid cancers that have returned or not responded to treatment. It may help shrink the cancer or control it when other treatments have failed or are not possible.
Duarte, CaliforniaAges 12–95 - NCT04466059Recruiting
AI tool for leukemia diagnosis using blood or marrow samples
This study tests whether an AI (computer system) can help improve leukemia and related blood cancer diagnoses. You may be able to help if your doctor is already evaluating you for a possible blood disorder and your sample is high enough quality for testing.
Munich, BavariaAges 18 years+ - NCT04503265RecruitingPhase 1/Phase 2
AMXI-5001 study for advanced cancers that won’t respond
This Phase 1/2 trial tests AMXI-5001 in people with advanced cancers that have progressed or stopped responding to standard treatments. It’s mainly designed to find the safest dose and see early signs the treatment might work.
Los Angeles, CaliforniaAges 18 years+ - NCT04546945Recruiting
Test for CD56 in newly diagnosed blood cancers
This trial looks at a marker called CD56 in people who have been newly diagnosed with a blood cancer (a hematologic malignancy). The results may help doctors better understand the disease and guide future treatment choices.
AsyutAges Any age - NCT04547777RecruitingPhase 1
Early Phase brain tumor treatment with implanted device and injections
This Phase 1 study tests a new brain-tumor treatment in people with recurrent (coming back) high-grade glioma (brain cancer). The study uses injected medicine along with an implanted tumor device and aims to find whether the treatment is safe and can shrink or control tumors.
Durham, North CarolinaAges 18 years+ - NCT04584333Recruiting
Dentist care for alcohol-related mouth changes
This trial looks at whether a dentist-led approach can help control ongoing mouth conditions linked with heavy alcohol use. It focuses on adults with long-lasting mouth patches diagnosed by biopsy as oral lichen planus or oral leukoplakia.
Santiago de Compostela, A CoruñaAges 40 years+ - NCT04625556Recruiting
Urology cancer registry study using body microbiome data
This study builds a patient registry for prostate, kidney, bladder, and ureter cancers by analyzing your body’s microbiome (the microbes living in/ on the body). It may help doctors personalize care in the future, and your participation mainly involves allowing your medical and related information to be used for research.
SeoulAges 20 years+ - NCT04678648RecruitingPhase 1
Testing RSC-1255 in advanced cancers with RAS changes
This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT04684459RecruitingEarly Phase 1
CAR-T therapy for tumors with HER2 and PD-L1 markers
This early-phase trial tests CAR-T cells designed to attack tumors that have high HER2 and PD-L1. It may help people with certain solid cancers that have not responded well to standard treatment.
Chengdu, SichuanAges 18–75 - NCT04693377Recruiting
Freezing tumor treatment plus targeted radiation for painful bone spread
This study tests whether combining a “freezing” procedure (cryoablation) with focused external radiation (SBRT) can reduce pain from bone metastases. It’s for people with certain cancers that have spread to bone and are having significant pain in a specific bone spot.
Houston, TexasAges 18 years+ - NCT04732065RecruitingPhase 1
ONC206 for certain brain tumors in children and young adults
This Phase 1 study tests ONC206, a new targeted medicine, for diffuse midline gliomas (DMG) with a specific gene change (H3K27 altered) and for some other recurrent brain/spinal cord cancers. It is designed to find the right dose and see whether it can control or shrink tumors after initial treatment or when the cancer returns.
San Francisco, CaliforniaAges 2–21 - NCT04752826RecruitingPhase 1/Phase 2
Testing BI-1808 plus Keytruda for advanced cancers
This trial tests a new cancer medicine (BI-1808) either alone or together with Keytruda (pembrolizumab) in people with advanced cancers. It may help by strengthening the immune system’s attack on cancer, especially if standard treatments are no longer working or aren’t suitable.
Duarte, CaliforniaAges 18 years+ - NCT04806412Recruiting
Gene testing in lung cancer fluid samples
This study looks at fluid from around the lungs (pleural fluid) to find gene changes (oncodrivers) in people with non-small cell lung cancer. The goal is to see if this fluid can replace a tissue biopsy for testing.
Næstved, Region SjællandAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Birmingham, AlabamaAges 1–30
Hear when a new Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignancy?
- Yes. Clin2 currently lists 1,585 recruiting malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.